BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38404964)

  • 1. Analytical validation and clinical utilization of K-4CARE™: a comprehensive genomic profiling assay with personalized MRD detection.
    Nguyen Hoang TP; Nguyen TA; Tran NHB; Nguyen Hoang VA; Thi Dao HT; Tran VU; Nguyen YN; Nguyen AT; Nguyen Thi CT; Do Thi TT; Nguyen DS; Nguyen HN; Giang H; Tu LN
    Front Mol Biosci; 2024; 11():1334808. PubMed ID: 38404964
    [No Abstract]   [Full Text] [Related]  

  • 2. An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing.
    Malhotra R; Javle V; Tanwar N; Gowda P; Varghese L; K A; Madhusudhan N; Jaiswal N; K S B; Chatterjee M; Prabhash K; Sreekanthreddy P; Rishi KD; Goswami HM; Veldore VH
    Front Oncol; 2023; 13():1002792. PubMed ID: 36994199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay.
    Powles T; Young A; Nimeiri H; Madison RW; Fine A; Zollinger DR; Huang Y; Xu C; Gjoerup OV; Aushev VN; Wu HT; Aleshin A; Carter C; Davarpanah N; Degaonkar V; Gupta P; Mariathasan S; Schleifman E; Assaf ZJ; Oxnard G; Hegde PS
    Front Oncol; 2023; 13():1221718. PubMed ID: 37601688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden.
    Lee KS; Seo J; Lee CK; Shin S; Choi Z; Min S; Yang JH; Kwon WS; Yun W; Park MR; Choi JR; Chung HC; Lee ST; Rha SY
    Clin Chem; 2022 Dec; 68(12):1519-1528. PubMed ID: 36306340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.
    Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W
    Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Validation of a Comprehensive Targeted Panel for Broad Mutational and Biomarker Analysis in Solid Tumors.
    Froyen G; Geerdens E; Berden S; Cruys B; Maes B
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA.
    Poh J; Ngeow KC; Pek M; Tan KH; Lim JS; Chen H; Ong CK; Lim JQ; Lim ST; Lim CM; Goh BC; Choudhury Y
    PLoS One; 2022; 17(4):e0267389. PubMed ID: 35486650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.
    Milbury CA; Creeden J; Yip WK; Smith DL; Pattani V; Maxwell K; Sawchyn B; Gjoerup O; Meng W; Skoletsky J; Concepcion AD; Tang Y; Bai X; Dewal N; Ma P; Bailey ST; Thornton J; Pavlick DC; Frampton GM; Lieber D; White J; Burns C; Vietz C
    PLoS One; 2022; 17(3):e0264138. PubMed ID: 35294956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing.
    Al Zoughbi W; Fox J; Beg S; Papp E; Hissong E; Ohara K; Keefer L; Sigouros M; Kane T; Bockelman D; Nichol D; Patchell E; Bareja R; Karandikar A; Alnajar H; Cerqueira G; Guthrie VB; Verner E; Manohar J; Greco N; Wilkes D; Tagawa S; Malbari MS; Holcomb K; Eng KW; Shah M; Altorki NK; Sboner A; Nanus D; Faltas B; Sternberg CN; Simmons J; Houvras Y; Molina AM; Angiuoli S; Elemento O; Mosquera JM
    Oncologist; 2021 Nov; 26(11):e1971-e1981. PubMed ID: 34286887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy.
    Li G; Pavlick D; Chung JH; Bauer T; Tan BA; Peguero J; Ward P; Kallab A; Bufill J; Hoffman A; Sadiq A; Edenfield J; He J; Cooke M; Hughes J; Forcier B; Nahas M; Stephens P; Ali SM; Schrock AB; Ross JS; Miller VA; Gregg JP
    J Gastrointest Oncol; 2019 Oct; 10(5):831-840. PubMed ID: 31602320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of Circulating Tumor DNA with a Single-Molecule Sequencing Analysis Validated for Targeted and Immunotherapy Selection.
    Atkins A; Gupta P; Zhang BM; Tsai WS; Lucas J; Javey M; Vora A; Mei R
    Mol Diagn Ther; 2019 Aug; 23(4):521-535. PubMed ID: 31209714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.
    Zhao J; Reuther J; Scozzaro K; Hawley M; Metzger E; Emery M; Chen I; Barbosa M; Johnson L; O'Connor A; Washburn M; Hartje L; Reckase E; Johnson V; Zhang Y; Westheimer E; O'Callaghan W; Malani N; Chesh A; Moreau M; Daber R
    Mol Diagn Ther; 2023 Nov; 27(6):753-768. PubMed ID: 37632661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study.
    Chauhan PS; Chen K; Babbra RK; Feng W; Pejovic N; Nallicheri A; Harris PK; Dienstbach K; Atkocius A; Maguire L; Qaium F; Szymanski JJ; Baumann BC; Ding L; Cao D; Reimers MA; Kim EH; Smith ZL; Arora VK; Chaudhuri AA
    PLoS Med; 2021 Aug; 18(8):e1003732. PubMed ID: 34464379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analytic validation of NeXT Dx™, a comprehensive genomic profiling assay.
    Saldivar JS; Harris J; Ayash E; Hong M; Tandon P; Sinha S; Hebron PM; Houghton EE; Thorne K; Goodman LJ; Li C; Marfatia TR; Anderson J; Morra M; Lyle J; Bartha G; Chen R
    Oncotarget; 2023 Aug; 14():789-806. PubMed ID: 37646774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
    Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
    Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection.
    Lonardi S; Nimeiri H; Xu C; Zollinger DR; Madison RW; Fine AD; Gjoerup O; Rasola C; Angerilli V; Sharma S; Wu HT; Palsuledesai CC; Malhotra M; Aleshin A; Loupakis F; Renkonen E; Hegde P; Fassan M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-genome informed circulating tumor DNA analysis by multiplex digital PCR for disease monitoring in B-cell lymphomas: a proof-of-concept study.
    Haider Z; Wästerlid T; Spångberg LD; Rabbani L; Jylhä C; Thorvaldsdottir B; Skaftason A; Awier HN; Krstic A; Gellerbring A; Lyander A; Hägglund M; Jeggari A; Rassidakis G; Sonnevi K; Sander B; Rosenquist R; Tham E; Smedby KE
    Front Oncol; 2023; 13():1176698. PubMed ID: 37333831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.
    Verma S; Moore MW; Ringler R; Ghosal A; Horvath K; Naef T; Anvari S; Cotter PD; Gunn S
    BMC Cancer; 2020 Oct; 20(1):945. PubMed ID: 33004033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors.
    Conroy JM; Pabla S; Glenn ST; Seager RJ; Van Roey E; Gao S; Burgher B; Andreas J; Giamo V; Mallon M; Lee YH; DePietro P; Nesline M; Wang Y; Lenzo FL; Klein R; Zhang S
    PLoS One; 2021; 16(12):e0260089. PubMed ID: 34855780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.